Preclinical antitumor activity of XK469 (NSC 656889)
Effect of the cisplatin-procaine complex DPR in combination with several anticancer agents on murine P388 leukemic cells in vitro and in vivo
Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations
PALA Versus streptozotocin, doxorubicin, and MeCCNU in the treatment of patients with advanced pancreatic carcinoma
Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion
A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors
Phase II study of Didemnin B in central nervous system tumors : A Southwest Oncology Group study
Oral etoposide for patients with advanced adenocarcinoma of the pancreas
A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma
Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hour continuous infusion weekly for three weeks in metastatic colorectal carcinoma
Phase II trial of edatrexate in relapsed or refractory germ cell tumors : A Southwest Oncology Group study (SWOG 9124)
A phase II trial of irinotecan in hormone-refractory prostate cancer
Contents Volume 16, 1998/1999
Instructions for authors